Augmented Response of Volatile Biomarkers in Assessment of Oesophagogastric Cancer (AROMA 1 / BIORESOURCE)
Recruiting now · Not applicable
Conditions studied: Volatile Organic Compounds, Microbiome, Microbioata, Breath Analysis, Oesophageal Cancer, Gastric Cancer, Volatalomics, Metabonomics/Lipidomics, Microbiome Analysis, Transcriptomics
In brief
Cancer of the stomach and oesophagus is among the world's top five cancers. Survival rates are very poor as the disease presents late and early symptoms are non-specific. The study team has developed a non-invasive test for cancers of the stomach and oesophagus based on the detection of volatile organic compounds in exhaled breath. These compounds are known to be produced by both cancers as well as cancer associated bacteria within the gut. The proposed innovation is to improve the accuracy of this test by investigating whether simple metabolic substrates can increase the production of these volatile organic compounds by both the tumour and its associated bacteria.
Key facts
- Study ID
- NCT05412758
- Run by
- Imperial College London
- People needed
- 648
- Starts
- 2022-02-28
- Expected to finish
- 2025-10-01
- Last updated by the study team
- 2025-01-31
Who can join
Age: 18 and older, up to 90. Sex: any. Healthy volunteers: accepted.
Where it is running
- Imperial College NHS Foundation Trust — London, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.